Printer-friendly versionPrinter-friendly version

Prevention and control of viral hepatitis in the Russian Federation in the Russian Federation: Lessons learnt and the way forward 

October 25-26, 2018 - Moscow, Russia
 
Meeting objectives:
  • Review the epidemiological situation on viral hepatitis and burden of disease in the Russian Federation;
  • Provide an overview of surveillance systems for viral hepatitis and infectious diseases;
  • Discuss achievements and challenges in the prevention of viral hepatitis, the possible implementation of new prevention strategies in Russia;
  • Give an overview of the current approaches to chronic viral hepatitis treatment;
  • Discuss the current issues of organization of medical care and access to treatment for patients with viral hepatitis;
  • Discuss the development and implementation of a national plan of action to control viral hepatitis in Russia;
  • Evaluate what is still needed to achieve the viral hepatitis elimination goals defined by WHO Global Strategy and WHO’s Regional office for Europe
  • Discuss the successes, issues and barriers to overcome, and the way forward.
Background document (Pdf, 2.764 kB - EN)
 
 
Thursday, October 25th
 
OPENING AND OBJECTIVES
Chairs: Pierre Van Damme (VHPB, Belgium) and Vladimir Chulanov (Russia)
 
09:00-09:20
  • Welcome and opening
  • Introduction of the participants
  • Introduction of the VHPB
  • Objectives of the meeting:
  • Review of the meeting programme
Welcome by:
  • The Russian Federation Ministry of Health representative
  • Rospotrebnarzor representative
  • Rector/Vice-rector of Sechenov University
  • The WHO Representative in the Russian Federation
  • VHPB Executive Secretary
 
SESSION 1: THE HEALTH CARE SYSTEM IN THE RUSSIAN FEDERATION
Chairs: Daniel Lavanchy (VHPB, Switzerland) and Igor Nikitin (Russia) 
 
09:20 - 09:35 The structure and priority directions of the health care system development in the Russian Federation. (Pdf, 1.176 kB - EN)
Ekaterina Karakulina, Department of the organization of medical care and sanatorium affairs, Ministry of Health of the Russian Federation, Moscow.
 
Elena Malinnikova, Chief Specialist on infectious diseases of MoH, Moscow;
Vladimir Gorodin, Chief Specialist on Infectious Diseases in the Southern Federal district, Krasnodar.
 
Natalia Kostenko, Department of Science, Innovative Development and Management of Medical and Biological Health Risks, Ministry of Health, Moscow.
 
10:05 - 10:20 Challenges and prospects of the organization and financing of medical care.
Vitaly Omelyanovskiy, Center for Healthcare Quality Assessment and Control of the Russian Federation MoH, Moscow.
 
 
10:20 - 10:30 Questions and discussion
 
 
 
SESSION 2: SURVEILLANCE AND EPIDEMIOLOGY OF VIRAL HEPATITIS IN RUSSIA
Chairs: Helène Norder (VHPB, Sweden) and Elena Malinnikova (Russia)
 
Vladimir Chulanov, Central Research Institute of Epidemiology, Moscow.
 
Mikhail Mikhailov, Russian Medical Academy of Continuous Professional Education, Moscow.
 
Elena Esaulenko, Pasteur Institute of Epidemiology and Microbiology, Saint Petersburg.
 
Olga Isayeva, I.I. Mechnikov Institute of vaccines and sera, Moscow.
 
Nikolay Pimenov, Central Research Institute of Epidemiology, Moscow.
 
State-of-art lecture
 
12:30 - 12:50 WHO guidelines on surveillance for viral hepatitis. (Pdf, 703 kB - EN)
Antons Mozalevskis, WHO Regional Office for Europe, Copenhagen, Denmark.
 
12:50 - 13:00  Questions and discussion
 
 
SESSION 3: EPIDEMIOLOGY AND DISEASE BURDEN OF VIRAL HEPATITIS IN THE REGIONS OF THE RUSSIAN FEDERATION
Chairs: Paolo Bonanni (VHPB, Italy) and Olga Znoyko (Russia)
 
Olga Sagalova, Chief specialist on infectious diseases of the Chelyabinsk Region MoH, Chelyabinsk.
 
Viktoria Bakhtina, Specialized clinical infectious diseases hospital of Krasnodar Region MoH, Krasnodar.
 
Anna Simakova, The Far Eastern State Medical University, Vladivostok.
 
Snezhana Sleptsova, M.K.Amosov North-Eastern Federal University, Yakutsk.
 
Marina Ivanova, AIDS and Infectious Diseases Center of the Kabardino-Balkaria Republic MoH, Nalchik.
 
Alexey Krapivkin, Chukotka District Hospital, Anadyr.
 
State-of-art lecture
 
John Ward, Centers for Disease Control and Prevention, Atlanta, USA.
 
15:20 - 15:30 Questions and discussion
 
 
SESSION 4: PREVENTION OF VIRAL HEPATITIS. VIRAL HEPATITIS IN RISK GROUPS.
Chairs: Françoise Roudot-Thoraval  (VHPB, France) and Elena Esaulenko (Russia)
 
15:50 - 16:05 Hepatitis B vaccination program in the Russian Federation: achievements and prospects. (Pdf, 3.416 kB - RU)
Svetlana Komarova, Central Research Institute of Epidemiology, Moscow.
 
16:05 - 16:20 Control of hepatitis A through routine vaccination: experience of the Tyva Republic. (Pdf, 3.025 kB - EN)
Anna Saryglar, Chief specialist on infectious diseases of the Tyva Republic, Kyzyl.
 
16:20 - 16:35 The risk of transmission of viral hepatitis in health care settings. (Pdf, 807 kB - EN)
Tatiana Semenenko, Arpik Asratyan, Gamaleya National Research Center for Epidemiology and Microbiology, Moscow
 
16:35 - 16:50 Viral hepatitis B and C among PWID. (Pdf, 863 kB - RU)
Ekaterina Zinger, Charitable Foundation "Humanitarian Action", Saint Petersburg.
 
State-of-art lecture
 
16:50 - 17:20 Current strategies of hepatitis A vaccination. (Pdf, 3.046 kB - EN)
Daniel Shouval, Hadassah Hebrew University Hospital, Jerusalem, Israel.
 
17:20 - 17:40 Hepatitis B vaccination worldwide: lessons learnt and the way forward. (Pdf, 3.176 kB - EN)
Pierre Van Damme, Vaccine and Infectious Diseases Institute, Antwerp University, Antwerp, Belgium. 
 
17:40 - 17:50 Questions and discussion
 
 
SESSION 5: THE ROLE OF CIVIL SOCIETY IN THE RESPONS TO VIRAL REPATITIS IN RUSSIA
Chairs: Tatjana Reic (VHPB, Croatia) and Yury Zhulev (Russia)
 
17:50 - 18:05 Health care for viral hepatitis in Russia from the patients’ perspective. (Pdf, 422 kB - EN)
Nikita Kovalenko, Interregional non-government patient advocacy organization “United against hepatitis”, Moscow.
 
18:05 - 18:20 Improving access to antiviral treatment: experience and prospects. (Pdf, 246 kB - EN)
Sergey Golovin, The International Treatment Preparedness Coalition: Eastern Europe and Central Asia, Moscow.
 
18:20 - 18:30 Questions and discussion
 
 
Friday, October 26th
 
 
SESSION 6: WHO GLOBAL HEALTH SECTOR STRATEGY AND EUROPEAN PLAN OF ACTION ON VIRAL HEPATITIS. TREATMENT OF VIRAL HEPATITIS.
Chairs: David Goldberg (VHPB, Scotland) and Olga Sagalova (Russia)
 
09:00 - 09:15 International and Russian guidelines on treatment of hepatitis B and D. (Pdf, 2.210 kB - EN)
Dzhamal Abdurakhmanov, I.M.Sechenov First Moscow State Medical University, Moscow.
 
09:15 - 09:30 EASL guidelines on treatment of hepatitis C through the prism of Russian realities. (Pdf, 2.367 kB - EN)
Sergey Batskikh, A.S. Loginov Moscow Clinical Scientific Center; Central Research Institute of Epidemiology, Moscow.
 
09:30 - 09:45 Socio-economic burden and access to treatment of chronic hepatitis C in the Russian Federation. (Pdf, 1.228 kB - EN)
Olga Znoyko, A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Moscow.
 
09:45 - 10:00 The system of drug supply of patients with viral hepatitis in the Russian Federation: how to make treatment more accessible?
Elena Maksimkina,  Department of drug supply and regulation of  medical products handling, Ministry of Health, Moscow.
 
10:00 - 10:15 Economic aspects of the organization of medical care in infectious diseases. (Pdf, 1.086 kB - EN)
Inna Zheleznyakova, Center for Healthcare Quality Assessment and Control of the Russian Federation MoH, Moscow.
 
State-of-art lecture
 
10:15 - 10:35 WHO Global Strategy and the European action plan on viral hepatitis elimination. WHO guidelines for treatment of chronic hepatitis B and C. (Pdf, 1.1675 kB - EN)
Antons Mozalevskis, WHO Regional Office for Europe, Copenhagen, Denmark.
 
10:35 - 10:45 Questions and discussion
 
 
SESSION 7: NATIONAL ACTION PLAN ON ELIMINATION OF VIRAL HEPATITIS AS A PUBLIC HEALTH THREAT IN THE RUSSIAN FEDERATION BY 2030: STRATEGIC DIRECTIONS,  PRIORITIES AND TARGETS
Chairs: Liudmila Mosina  (VHPB, WHO-Euro) and Dzhamal Abdurakhamnov (Russia)
 
11:00 - 12:15 Discussion in groups: What needs to be done to achieve the targets for eliminating viral hepatitis in Russia by 2030?
  • Group 1 - Epidemiological surveillance, screening, monitoring and analysis of the effectiveness of prevention and treatment programs, informing the public
  • Group 2 - Prevention of viral hepatitis: improvement of vaccine prevention programs, prevention in high-risk groups, prevention in health care settings
  • Group 3 - Treatment of viral hepatitis: recommendations based on epidemiology and disease burden data, increasing access to treatment, coverage of the most affected groups
  • Group 4 - Funding of screening, prevention and treatment programs: mechanisms for ensuring sustainable financing, dialogue between the state and pharmaceutical companies, prospects for reducing prices for medicines, financing of treatment in outpatient settings
  • Group 5 - Innovations in health care: research priorities, mechanisms to promote scientific development, accelerate the introduction of promising developments in the practice
12:15 - 12:45 Presentation of the results of the discussion in groups
 
 
SESSION 8: PANEL DISCUSSION: " INCREASING THE ACCESS TO TREATMENT OF CHRONIC VIRAL HEPATITIS IN THE RUSSIAN FEDERATION: THE ROLE OF THE STATE, BUSINESS AND THE PROFESSIONAL COMMUNITY "
 
12:45 - 13:45  Panel members: Moderator Mojca Maticic (VHPB, Slovenia)
  • Antons Mozalevskis, WHO Regional Office for Europe;
  • Elena Maksimkina,  Department of drug supply and regulation of  medical products handling, Ministry of Health;
  • Igor Nikitin, Therapeutic and rehabilitation center of the Russian Federation MoH;  Pirogov Russian National Research Medical University;
  • Inna Zheleznyakova, Center for Healthcare Quality Assessment and Control of the Russian Federation MoH;
  • Elena Malinnikova, Chief Specialist on infectious diseases of the Russian Federation MoH;
  • Vladimir Chulanov, Central Research Institute of Epidemiology;
  • Mikhail Samsonov, Pharmaceutical company “R-Pharm”;
  • Sergey Golovin, The International Treatment Preparedness Coalition: Eastern Europe and Central Asia
 
SESSION 9: CONCLUSIONS OF THE MEETING
Chairs: Pierre Van Damme (VHPB, Belgium) and Vladimir Chulanov (Russia)
 

 

 

 

Tags: